A Randomized Phase II Study Comparing Cytarabine + Daunorubicin 7+3 vs Daunorubicin and Cytarabine Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and Daunorubicin and Cytarabine Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk Adverse Acute Myeloid Leukemia as Determined by MYELOMATCH; A MYELOMATCH CLINICAL TRIAL

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05554406

Study #:
STUDY00160784

Start Date:
Aug 05, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05554406

View Complete Trial Details & Eligibility at ClinicalTrials.gov